Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine
Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day. Pfizer has sole commercial responsibility for the candidate, VLA15, which is currently in Phase 3. Pending those results, Lingelbach said a 2026 regulatory filing may be in reach,